BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 10803497)

  • 41. Presentation of HIV V3 loop epitopes for enhanced antigenicity, immunogenicity and diagnostic potential.
    Fontenot JD; VanCott TC; Parekh BS; Pau CP; George JR; Birx DL; Zolla-Pazner S; Gorny MK; Gatewood JM
    AIDS; 1995 Oct; 9(10):1121-9. PubMed ID: 8519447
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr.
    Sarobe P; Lasarte JJ; Golvano JJ; Prieto I; Gullón A; Soto MJ; Labarga P; Prieto J; Borrás-Cuesta F
    J Acquir Immune Defic Syndr (1988); 1994 Jul; 7(7):635-40. PubMed ID: 8207641
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope.
    Zolla-Pazner S; Cohen SS; Krachmarov C; Wang S; Pinter A; Lu S
    Virology; 2008 Mar; 372(2):233-46. PubMed ID: 18061228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice.
    Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O
    J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490
    [TBL] [Abstract][Full Text] [Related]  

  • 45. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
    Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A
    AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
    Liao HX; Cianciolo GJ; Staats HF; Scearce RM; Lapple DM; Stauffer SH; Thomasch JR; Pizzo SV; Montefiori DC; Hagen M; Eldridge J; Haynes BF
    Vaccine; 2002 May; 20(17-18):2396-403. PubMed ID: 12009296
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
    Letvin NL; Robinson S; Rohne D; Axthelm MK; Fanton JW; Bilska M; Palker TJ; Liao HX; Haynes BF; Montefiori DC
    J Virol; 2001 May; 75(9):4165-75. PubMed ID: 11287566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120.
    Chen H; Xu X; Lin HH; Chen SH; Forsman A; Aasa-Chapman M; Jones IM
    J Gen Virol; 2008 Oct; 89(Pt 10):2597-2604. PubMed ID: 18796729
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines.
    Coëffier E; Excler JL; Kieny MP; Meignier B; Moste C; Tartaglia J; Pialoux G; Salmon-Céron D; Leclerc C
    AIDS Res Hum Retroviruses; 1997 Nov; 13(17):1471-85. PubMed ID: 9390746
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
    Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
    J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins.
    He Y; D'Agostino P; Pinter A
    Vaccine; 2003 Oct; 21(27-30):4421-9. PubMed ID: 14505925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
    Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
    Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41.
    Dong XN; Xiao Y; Chen YH
    Immunol Lett; 2001 Jan; 75(2):149-52. PubMed ID: 11137140
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An immunoassay with bovine serum albumin coupled peptides for the improved detection of anti V3 antibodies in HIV-1 positive human sera.
    Gómez CE; López-Campistrous AE; Duarte CA
    J Virol Methods; 1998 Mar; 71(1):7-16. PubMed ID: 9628216
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody responses raised against a conformational V3 loop peptide of HIV-1.
    Bukawa H; Fukushima J; Hamajima K; Kimura M; Tsuji T; Xin KQ; Okuda K
    Microbiol Immunol; 1995; 39(8):607-14. PubMed ID: 7494500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.